T60	SPAN 360 380	TCRzeta and p56(lck)
R8	Coref Anaphora:T37 Antecedent:T60
R9	Coref Anaphora:T40 Antecedent:T41
R10	Coref Anaphora:T51 Antecedent:T59
T1	Protein 360 367	TCRzeta
T2	Protein 372 380	p56(lck)
T3	Protein 450 454	RelA
T4	Protein 844 851	TCRzeta
T5	Protein 853 861	p56(lck)
T6	Protein 1021 1039	interleukin (IL)-2
T7	Protein 1041 1050	IFN alpha
T8	Protein 1135 1142	TCRzeta
T9	Protein 1147 1155	p56(lck)
T10	Protein 1778 1785	TCRzeta
T11	Protein 1790 1798	p56(lck)
T12	Protein 2057 2064	TCRzeta
T13	Protein 2081 2089	p56(lck)
T14	Protein 2110 2120	CD3epsilon
T15	Protein 2201 2205	IL-2
T16	Protein 2206 2215	IFN alpha
T17	Protein 2250 2257	TCRzeta
T18	Protein 2361 2368	TCRzeta
T19	Protein 2372 2380	p56(lck)
T20	Protein 2441 2448	TCRzeta
T21	Protein 3009 3016	TCRzeta
T22	Protein 3062 3069	TCRzeta
T23	Protein 3213 3220	TCRzeta
T24	Protein 3225 3233	p56(lck)
T25	Protein 3276 3283	TCRzeta
T26	Protein 3468 3472	IL-2
T27	Protein 3474 3482	FN alpha
T28	Protein 3588 3595	TCRzeta
T59	Exp 2851 2866	six individuals
T36	Exp 192 223	the CD3/T-cell antigen receptor
T37	Exp 381 385	that
T38	Exp 406 413	the TCR
T39	Exp 526 539	These defects
T40	Exp 971 975	whom
T41	Exp 955 967	the majority
T42	Exp 1109 1123	these patients
T43	Exp 1469 1484	the first group
T44	Exp 1487 1500	the frequency
T45	Exp 1816 1844	the peripheral blood T cells
T46	Exp 1979 1983	When
T47	Exp 2331 2343	the baseline
T48	Exp 2471 2483	the presence
T49	Exp 2713 2729	the advanced age
T50	Exp 2733 2749	the study cohort
T51	Exp 2867 2870	who
T52	Exp 3314 3318	that
T53	Exp 3136 3148	the majority
T54	Exp 3270 3283	these TCRzeta
T55	Exp 3551 3563	the presence
T56	Exp 3500 3515	This alteration
T57	Exp 3627 3652	The clinical significance
T58	Exp 3656 3670	these findings
